It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

NVF M&A Exits: Our Successes

Since its foundation in 1996, the Novartis Venture Fund has developed exit strategies that have helped guide over 30 of its portfolio companies to successfully complete transformational M&A transactions with a diverse group of large international pharmaceutical companies.

Explore our M&A successes

Ablation Frontiers

Ablation Frontiers was acquired by Medtronic, Inc. in 2009.

Adenosine Therapeutics

Adenosine Therapeutics was acquired by Clinical Data, Inc. in 2008.

Alios BioPharma

Alios BioPharma was acquired by Johnson & Johnson in 2014.

Arctos Medical

Arctos Medical was acquired by Novartis in 2021.

Avila Therapeutics

Avila Therapeutics was acquired by Celgene Corp. in 2012.


Cavion was acquired by Jazz Pharmaceuticals in 2019.

Cequent Pharmaceuticals

Cequent Pharmaceuticals was acquired by Marina Biotech in 2010.


Covagen AG was acquired by Johnson & Johnson in 2014.

Discovery Technologies

Discovery Technologies was acquired by Discovery Partners in 1999.

Enterprise TMEM16A

Enterprise Therapeutics' novel TMEM16A potentiator portfolio was acquired by Roche in 2020.

EraGen Biosciences

EraGen Biosciences was acquired by Luminex Corporation in 2011.


ESBATech was acquired by Alcon in 2009.

FoldRx Pharmaceuticals

FoldRx Pharmaceuticals was acquired by Pfizer, Inc. in 2010.

Forendo Pharma 

Forendo Pharma was acquired by Organon in 2021.

Genedata AG

NVF’s holdings in Genedata were acquired by Genedata in 2019.

GlycArt Biotechnology

GlycArt Biotechnology was acquired by Roche in 2005.

Heptares Therapeutics, Ltd 

Heptares Therapeutics, Ltd was acquired by Sosei Group Corporation in 2015.


Inflazome was acquired by Roche in 2020.


Intellikine was acquired by Takeda Pharmaceutical Company Ltd. in 2012.

Kinetix Pharmaceuticals

Kinetix Pharmaceuticals was acquired by Amgen in 2004.

KuDOS Pharmaceuticals 

KuDOS Pharmaceuticals was acquired by AstraZeneca in 2006.

Lemonaid Health

Lemonaid Health was acquired by 23andMe in 2021.

LigoCyte Pharmaceuticals

LigoCyte Pharmaceuticals was acquired by Takeda Pharmaceutical Company Ltd. In 2012.

Miikana Therapeutics 

Miikana Therapeutics was acquired by EntreMed, Inc. (now CASI Pharmaceuticals, Inc.) in 2006.


Neurovance was acquired by Otsuka Pharmaceuticals in 2017.


Okairos was acquired by GlaxoSmithKline in 2013.


Symetis was acquired by Boston Scientific in 2017.


Syrxx was acquired by Takeda Pharmaceutical Company Ltd. In 2006.

Swiss Pharma Contract 

Swiss Pharma Contract was acquired by Covance, Inc. in 2009.

Transform Pharmaceuticals 

Transform Pharmaceuticals was acquired by Johnson & Johnson in 2005.


Viamet’s clinical-stage antifungal portfolio acquired by NovaQuest Capital Management in 2018.


Visiogen was acquired by Abbott Laboratories in 2009.

Our investment team has proven experience

With successful backgrounds in medicine, science, legal, investment, and business development, our team has expertise in bringing exciting new drugs and treatments to patients all over the world.

Learn about our IPO successes

Since 1999, the Novartis Venture Fund team has guided a number of life science companies to IPO exits.